

Press Release

Martin Kunze
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2115
F +49 6172 608-2294
Martin.kunze@fresenius.com
www.fresenius.com

January 26, 2015

Fresenius Kabi and Halyard Health enter Supply and Distribution Agreement for Halyard Health Elastomeric I.V. Infusion Pumps

Fresenius Kabi, a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, will distribute Halyard Homepump Eclipse and Homepump C-Series Ambulatory Infusion Systems manufactured by Halyard Health, a global leader in disposable elastomeric infusion pumps, under an agreement signed by the two companies. The multi-year agreement covers several European markets including Germany, Spain, Poland, Switzerland and Austria. The UK and Ireland which were already part of a multi-year distribution arrangement between Fresenius Kabi and Halyard Health will also come under the terms of this larger agreement.

The Homepump Eclipse and Homepump C-Series Ambulatory Infusion Systems are disposable, ambulatory infusion pumps that deliver prescribed medication through a catheter. Their light weight, compact size and proven ease of use facilitate patient mobility and allow patients to receive therapy in the comfort of their homes.

The market for disposable infusion pumps is forecasted to post strong growth in the coming years due to the continuing shift to ambulatory care. Elastomeric I.V. devices can be used for a variety of therapies, including the administration of antibiotics and chemotherapy.

Christian Hauer, President of the Medical Devices Division of Fresenius Kabi, said: "This agreement demonstrates the company's continued commitment to our philosophy of 'caring for life'. By partnering with Halyard Health, we will be able to offer our customers an expanded range of products centered on key intravenously administered therapies, such as oncology and antibiotic treatment."

About Halyard Health Homepump Ambulatory Infusion Systems

The Homepump Eclipse and Homepump C-Series Ambulatory Infusion Systems offer a complete family of products for infusion needs.

- Homepump Eclipse system: this pump is designed for antibiotic therapy, providing delivery times ranging from 30 minutes to 5 hours.
- Homepump C-Series system: the portable pump for continuous infusion, with delivery times ranging from 1 to 11 days for chemotherapy and other protocols.

Homepump Eclipse and Homepump C-Series Ambulatory Infusion Systems combine high quality standards with the volumes and flow rates that caregivers need for successful drug delivery. The pumps' portability and proven ease of use allow patients to receive therapy in the comfort of their homes.

For questions about Halyard Health Homepump Ambulatory Infusion Systems, please contact:

Andrew Hyncik
Vice President Marketing
Global Business Unit Application Devices
Fresenius Kabi
T: +33 4 76 67 10 43
Andrew.Hyncik@fresenius-kabi.com

#

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's portfolio comprises I.V. generic drugs, infusion therapies, clinical nutrition products and related medical devices. Within transfusion technologies, the company offers products for whole blood and blood components collection and processing, transfusion medicine and cell therapies.

Fresenius Kabi employs more than 32,000 people worldwide. In 2013, Fresenius Kabi's sales were €4,996 million. Fresenius Kabi AG is a 100% subsidiary of the healthcare group Fresenius SE & Co. KGaA. For more information, please visit the company's website at www.fresenius-kabi.com.

This release contains forward-looking statements these are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, Luc Depotter, John Ducker,
Dr. Christian Hauer, Manfred M. Köhler, Dr. Michael Schönhofen, Gerrit Steen
Chairman of the Supervisory Board: Dr. Ulf M. Schneider
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654